Gilead Sciences finalizes agreement with Tibotec Pharmaceuticals
15 November 2011 | By Gilead Sciences
Gilead Sciences, Inc. has entered into a license agreement with Tibotec Pharmaceuticals...
List view / Grid view
15 November 2011 | By Gilead Sciences
Gilead Sciences, Inc. has entered into a license agreement with Tibotec Pharmaceuticals...
5 November 2011 | By
New long-term data show no development of resistance...
26 October 2011 | By Bristol-Myers Squibb Company
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
24 October 2011 | By Gilead Sciences Inc
Gilead & GlobeImmune enter into an exclusive worldwide license & collaboration agreement...
5 October 2011 | By Gilead Sciences
Gilead Sciences, Inc. and Boehringer Ingelheim have entered into a licensing agreement...
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
5 September 2011 | By Gilead Sciences, Inc.
Change does not affect ongoing "All Oral" clinical trials evaluating multiple direct-acting antivirals in combination...
15 August 2011 | By Gilead Sciences
Phase 3 clinical trial met its primary objective...
10 August 2011 | By Gilead Sciences Inc
A new complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naïve adults...
8 August 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. has signed a definitive agreement...
12 July 2011 | By Gilead Sciences
Gilead Sciences, Inc. announced an expansion of its global access program...
28 June 2011 | By Gilead Sciences, Inc.
Development and commercialization of a new fixed-dose antiretroviral combination product...
13 June 2011 | By Gilead Sciences, Inc.
Gilead Sciences, Inc. is pleased to announce that Kevin Young, has been appointed a Commander of The British Empire...
5 May 2011 | By Gilead Sciences, Inc.
Gilead Sciences, Inc. has extended its funding support of the Gilead Sciences Research Centre at the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague...
20 April 2011 | By Gilead Sciences
Gilead & MicroDose Therapeutx have entered into an exclusive worldwide license...